More articles about Cancer | GenomeWeb

More articles about Cancer

The company said it will use the proceeds of the financing round to accelerate commercial adoption of its NGS-based personalized cancer treatment test.

The company expects Medicare coverage for its test to extend to intermediate prostate cancer patients this year, and it believes new data will help drive increased adoption.

The study compared five methods, including three based on Roche test kits and reagents, and suggested that a multiplexed test may be best to avoid false-negative results.

The company beat the consensus Wall Street estimate for the fourth quarter on the bottom line but missed the estimate on the top line.

The company said investors have agreed to purchase $5.6 million of common stock as well as warrants that, if exercised, could raise an additional $5.1 million.

The companies will work together to seek FDA clearance or approval for a number of biomarker and immuno-oncology assay kits for use on the MiSeqDx.

The company is developing a non-invasive test that analyzes only a small area of the genome to infer overall tumor mutational load to help guide immunotherapy use.

Under the deal, the parties will provide Perthera's Precision Cancer Analysis molecular profiling service to Hope for Stomach Cancer patients free of charge.

The companies will study the combination of their respective technologies for predicting patient responses to metastatic lung cancer immunotherapy.

The firm will apply the proceeds towards an early-stage clinical trial of a precision colorectal cancer vaccine.

The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.

The company is providing several of its Parsortix instruments to the CANCER-ID consortium as part of an effort to establish liquid biopsy in routine clinical practice.

The money will support efforts by the company to develop liquid biopsy methods that can serve patients that its current tissue-based testing does not.

Bellwether plans to commercialize liquid biopsy technology based on analyzing fragmentation patterns in cell-free DNA that can identify the tissue of origin.

The competition was established in 2015 to fund studies addressing the biggest challenges in cancer research.

Researchers showed it could differentiate pancreatic cancer cases from controls with high sensitivity, and believe it could work similarly for other cancers or in infectious disease.

Researchers identified mutations present prior to allogeneic hematopoietic stem cell transplantation that coincided with MDS survival and relapse.

The organizations will each contribute expertise in immunotherapy and epigenomics to improve cancer treatment options for patients. 

The test is designed to analyze the expression of microRNA biomarkers in indeterminate thyroid fine needle aspirate smears in order to differentiate benign thyroid nodules from malignant ones.

The contract provides coverage of ConfirmMDx testing at the Medicare rate for veterans within the VA health system.

Pages

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.